Apellis Pharmaceuticals shares are trading lower on continued downward momentum amid safety concerns regarding Syfovre.
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals' shares are experiencing a downward trend due to safety concerns about Syfovre.
July 18, 2023 | 4:19 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Apellis Pharmaceuticals' stock is trading lower due to safety concerns about Syfovre.
The safety concerns about Syfovre, a product of Apellis Pharmaceuticals, are causing a negative impact on the company's stock. This is due to the potential implications these concerns could have on the product's sales and the company's reputation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100